Abstract 1900P
Background
Safe and efficient venous access is a crucial aspect of modern medical therapy in oncology. Catheter-related bloodstream infections (CRBSIs) are among the most common complications in neutropenic cancer patients and are associated with high mortality rates. Clinical observations and current literature suggest a relationship between season and infection rates. In this retrospective study, we evaluated the seasonal impact on PORT-a-cath (PORT) infections in oncological patients.
Methods
From 2010 to 2017, 1,323 oncology patients at our center were enrolled, of whom 795 underwent planned or unplanned PORT explantation. Data collected included demographics, laboratory findings, and catheter-associated parameters. Patients suffered from both oncologic and hematologic diseases. Infection rates were calculated on a seasonal basis and compared using Fisher's exact test and logistic regression analysis.
Results
There were 176 PORT explantations (128 women; 48 men) during the warm season (June, July, August; average temperature 68.54°F or 20.3°C) and 619 PORT explantations (493 women; 126 men) during the cold season (September-May; average temperature 45.6°F or 7.56°C). The composition of the study cohorts was comparable, with an average age of 55.1 years. Out of 795 explantations, we observed 98 CRBSIs, indicating an infection rate of 12.32%. A statistically significant increase in CRBSIs was noted during the summer (18.75% vs. 10.50%), representing a 78% higher risk of infection. Logistic regression analysis identified 'season' as a significant predictor for infection, with a hazard ratio of 1.785 (95% CI: 1.105 to 2.885, p-value = 0.0179) in the warm season, while sex and age were also found to be strong predictors.
Conclusions
We demonstrated a significant increase in CRBSIs during the warm season compared to the cold season. These findings highlight the importance of considering timing for catheter implantation, specifying long-term application devices, and implementing prophylactic antibiotic regimes in oncological patient therapy management.
Clinical trial identification
12th of December 2018; Ethics vote number: 1190/2018.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1717TiP - CARE1 pragmatic clinical trial: First line randomised study platform to optimize treatment in patients with metastatic renal cell carcinoma
Presenter: Laurence Albiges
Session: Poster session 12
1822P - Incidence of cachexia and health resource use (HRU) in patients with breast, colorectal, lung, pancreatic, and prostate cancers
Presenter: Imran Ali
Session: Poster session 12
1823P - Significance of skeletal muscle measurement in cancer-associated cachexia screening
Presenter: Lynn Gottmann
Session: Poster session 12
1824P - Sarcopenia in advanced non-small cell lung cancer (NSCLC): Clinical impact and its biological correlates
Presenter: Filippo Dall'Olio
Session: Poster session 12
1826P - Risk factors and incidence of osteoporosis in patients with breast cancer according to gender
Presenter: Chang Ik Yoon
Session: Poster session 12
1827P - Bone health and body composition in prostate cancer: An italian consensus about prevention and management strategies
Presenter: Maria Concetta Cursano
Session: Poster session 12
1828P - A cross-sectional study investigating the current diagnostic & therapeutical approaches to bone metastases (BoM) in patients (pts) with non-small cell lung cancer (NSCLC)
Presenter: Sara Pilotto
Session: Poster session 12
1829P - Nutritional status assessment for patients with common cancer in a cancer hospital of southwest China
Presenter: Huiqing Yu
Session: Poster session 12
Resources:
Abstract
1830P - Comprehensive prognostic effects of inflammatory and nutritional markers to predict survival in women with breast cancer
Presenter: Susanna Hutajulu
Session: Poster session 12
1831P - Obesity and weight variations before treatment, seem to influence weight loss that happens during first-line metastatic lung adenocarcinoma
Presenter: Anthony Tarabay
Session: Poster session 12